TY - STD TI - Evaluate Pharma. World Preview 2015. 2015. http://info.evaluategroup.com/rs/607-YGS-364/images/wp15.pdf. Accessed 15 Feb 2016. UR - http://info.evaluategroup.com/rs/607-YGS-364/images/wp15.pdf ID - ref1 ER - TY - STD TI - European Commission—Joint Research Centre. The 2015 EU Industrial R&D investment scoreboard. http://iri.jrc.ec.europa.eu/scoreboard15.html. Accessed 15 Feb 2016. UR - http://iri.jrc.ec.europa.eu/scoreboard15.html ID - ref2 ER - TY - JOUR AU - Munos, B. PY - 2009 DA - 2009// TI - Lessons from 60 years of pharmaceutical innovation JO - Nat Rev Drug Discov VL - 8 UR - https://doi.org/10.1038/nrd2961 DO - 10.1038/nrd2961 ID - Munos2009 ER - TY - JOUR AU - Kola, I. AU - Landis, J. PY - 2004 DA - 2004// TI - Can the pharmaceutical industry reduce attrition rates? JO - Nat Rev Drug Discov VL - 3 UR - https://doi.org/10.1038/nrd1470 DO - 10.1038/nrd1470 ID - Kola2004 ER - TY - JOUR AU - Mullard, A. PY - 2011 DA - 2011// TI - 2010 FDA drug approvals JO - Nat Rev Drug Discov VL - 10 UR - https://doi.org/10.1038/nrd3370 DO - 10.1038/nrd3370 ID - Mullard2011 ER - TY - JOUR AU - Mullard, A. PY - 2012 DA - 2012// TI - 2011 FDA drug approvals JO - Nat Rev Drug Discov VL - 11 UR - https://doi.org/10.1038/nrd3657 DO - 10.1038/nrd3657 ID - Mullard2012 ER - TY - JOUR AU - Mullard, A. PY - 2013 DA - 2013// TI - 2012 FDA drug approvals JO - Nat Rev Drug Discov VL - 12 UR - https://doi.org/10.1038/nrd3946 DO - 10.1038/nrd3946 ID - Mullard2013 ER - TY - JOUR AU - Mullard, A. PY - 2014 DA - 2014// TI - 2013 FDA drug approvals JO - Nat Rev Drug Discov VL - 13 UR - https://doi.org/10.1038/nrd4239 DO - 10.1038/nrd4239 ID - Mullard2014 ER - TY - JOUR AU - Mullard, A. PY - 2015 DA - 2015// TI - 2014 FDA drug approvals JO - Nat Rev Drug Discov VL - 14 UR - https://doi.org/10.1038/nrd4545 DO - 10.1038/nrd4545 ID - Mullard2015 ER - TY - STD TI - Schuhmacher A, et al. Value creation in the pharmaceutical industry: the critical path to innovation. Wiley; 2016. ISBN 978-3-527-33913-6. ID - ref10 ER - TY - STD TI - 2014 CMR International Pharmaceutical R&D Factbook. ID - ref11 ER - TY - JOUR AU - Paul, S. M. PY - 2010 DA - 2010// TI - How to improve R&D productivity: the pharmaceutical industry’s grand challenge JO - Nat Rev Drug Discov VL - 9 ID - Paul2010 ER - TY - JOUR AU - DiMasi, J. A. PY - 2001 DA - 2001// TI - Risks in new drug development: approval success rates for investigational drugs JO - Clin Pharmacol Ther VL - 69 UR - https://doi.org/10.1067/mcp.2001.115446 DO - 10.1067/mcp.2001.115446 ID - DiMasi2001 ER - TY - JOUR AU - Prinz, F. PY - 2011 DA - 2011// TI - Believe it or not: how much can we rely on published data on potential drug targets? JO - Nat Rev Drug Discov VL - 10 UR - https://doi.org/10.1038/nrd3439-c1 DO - 10.1038/nrd3439-c1 ID - Prinz2011 ER - TY - JOUR AU - Bergren, R. PY - 2012 DA - 2012// TI - Outlook for the next 5 years in drug innovation JO - Nat Rev Drug Discov VL - 11 UR - https://doi.org/10.1038/nrd3744 DO - 10.1038/nrd3744 ID - Bergren2012 ER - TY - JOUR AU - Agarwal, P. PY - 2013 DA - 2013// TI - Novelty in the target landscape of the pharmaceutical industry JO - Nat Rev Drug Discov VL - 12 UR - https://doi.org/10.1038/nrd4089 DO - 10.1038/nrd4089 ID - Agarwal2013 ER - TY - JOUR AU - Sams-Dodd, F. PY - 2005 DA - 2005// TI - Target-based drug discovery: is something wrong? JO - Drug Discov Today VL - 10 UR - https://doi.org/10.1016/S1359-6446(04)03316-1 DO - 10.1016/S1359-6446(04)03316-1 ID - Sams-Dodd2005 ER - TY - JOUR AU - Swinney, D. C. AU - Anthony, J. PY - 2011 DA - 2011// TI - How were new medicines discovered? JO - Nat Rev Drug Discov VL - 11 UR - https://doi.org/10.1038/nrd3480 DO - 10.1038/nrd3480 ID - Swinney2011 ER - TY - JOUR AU - Scannell, J. W. PY - 2012 DA - 2012// TI - Diagnosing the decline in pharmaceutical R&D efficiency JO - Nat Rev Drug Discov VL - 11 UR - https://doi.org/10.1038/nrd3681 DO - 10.1038/nrd3681 ID - Scannell2012 ER - TY - JOUR AU - Pammolli, F. PY - 2011 DA - 2011// TI - The productivity crisis in pharmaceutical R&D JO - Nat Rev Drug Discov VL - 10 UR - https://doi.org/10.1038/nrd3405 DO - 10.1038/nrd3405 ID - Pammolli2011 ER - TY - JOUR AU - Arrowsmith, J. AU - Miller, P. PY - 2013 DA - 2013// TI - Trial Watch: phase II and Phase III attrition rates 2011–2012 JO - Nat Rev Drug Discov VL - 12 UR - https://doi.org/10.1038/nrd4090 DO - 10.1038/nrd4090 ID - Arrowsmith2013 ER - TY - JOUR AU - Cook, D. PY - 2014 DA - 2014// TI - Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework JO - Nat Rev Drug Discov VL - 13 UR - https://doi.org/10.1038/nrd4309 DO - 10.1038/nrd4309 ID - Cook2014 ER - TY - JOUR AU - DiMasi, J. A. PY - 2010 DA - 2010// TI - Trends in risks associated with new drug development: success rates for investigational drugs JO - Clin Pharmacol Ther VL - 87 UR - https://doi.org/10.1038/clpt.2009.295 DO - 10.1038/clpt.2009.295 ID - DiMasi2010 ER - TY - STD TI - Abrantes-Metz R et al. Pharmaceutical Development Phases: a duration analysis. Working paper no. 274. US Federal Trade Commission: Bureau of Economics. 2004. http://www.ftc.gov/be/workpapers/wp274.pdf. Accessed 15 Feb 2016. UR - http://www.ftc.gov/be/workpapers/wp274.pdf ID - ref24 ER - TY - JOUR AU - Hay, M. PY - 2014 DA - 2014// TI - Clinical development success rates for investigational drugs JO - Nat Biotechnol VL - 32 UR - https://doi.org/10.1038/nbt.2786 DO - 10.1038/nbt.2786 ID - Hay2014 ER - TY - JOUR AU - Kaitin, K. I. AU - DiMasi, J. A. PY - 2011 DA - 2011// TI - Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000–2009 JO - Clin Pharmacol Ther VL - 89 UR - https://doi.org/10.1038/clpt.2010.286 DO - 10.1038/clpt.2010.286 ID - Kaitin2011 ER - TY - JOUR AU - Dickson, M. AU - Gagnon, J. P. PY - 2004 DA - 2004// TI - Key factors in the rising cost of new drug discovery and development JO - Nat Rev Drug Discov VL - 3 UR - https://doi.org/10.1038/nrd1382 DO - 10.1038/nrd1382 ID - Dickson2004 ER - TY - JOUR AU - DiMasi, J. A. PY - 2003 DA - 2003// TI - The price of innovation: new estimates of drug development costs JO - J Health Econ VL - 23 UR - https://doi.org/10.1016/S0167-6296(02)00126-1 DO - 10.1016/S0167-6296(02)00126-1 ID - DiMasi2003 ER - TY - JOUR AU - DiMasi, J. A. PY - 1991 DA - 1991// TI - Cost of innovation in the pharmaceutical industry JO - J Health Econ VL - 10 UR - https://doi.org/10.1016/0167-6296(91)90001-4 DO - 10.1016/0167-6296(91)90001-4 ID - DiMasi1991 ER - TY - STD TI - Harper M. The truly staggering cost of inventing new drugs. 2012. http://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-newdrugs/#2ce906714477. UR - http://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-newdrugs/#2ce906714477 ID - ref30 ER - TY - JOUR AU - Danzon, P. M. PY - 2007 DA - 2007// TI - Mergers and acquisitions in the pharmaceutical and biotech industries JO - Manag Decis Econ VL - 28 UR - https://doi.org/10.1002/mde.1343 DO - 10.1002/mde.1343 ID - Danzon2007 ER - TY - JOUR AU - LaMattina, J. L. PY - 2011 DA - 2011// TI - The impact of mergers on pharmaceutical R&D JO - Nat Rev Drug Discov VL - 10 UR - https://doi.org/10.1038/nrd3514 DO - 10.1038/nrd3514 ID - LaMattina2011 ER - TY - JOUR AU - Ornaghi, C. PY - 2009 DA - 2009// TI - Mergers and innovation in big pharma JO - Int J Ind Organ VL - 27 UR - https://doi.org/10.1016/j.ijindorg.2008.04.003 DO - 10.1016/j.ijindorg.2008.04.003 ID - Ornaghi2009 ER - TY - JOUR AU - Comanor, W. S. AU - Scherer, F. M. PY - 2013 DA - 2013// TI - Mergers and innovation in the pharmaceutical industry JO - J Health Econ VL - 32 UR - https://doi.org/10.1016/j.jhealeco.2012.09.006 DO - 10.1016/j.jhealeco.2012.09.006 ID - Comanor2013 ER - TY - JOUR AU - DiMasi, J. A. PY - 2014 DA - 2014// TI - The impact of collaborative and risk-sharing innovation approaches on clinical and regulatory cycle times JO - Ther Innov Regul Sci VL - 48 UR - https://doi.org/10.1177/2168479014521419 DO - 10.1177/2168479014521419 ID - DiMasi2014 ER - TY - JOUR AU - Kruse, S. PY - 2014 DA - 2014// TI - Pharmaceutical RandD productivity: the role of alliances JO - J Commer Biotechnol VL - 20 UR - https://doi.org/10.5912/jcb632 DO - 10.5912/jcb632 ID - Kruse2014 ER - TY - JOUR AU - Garnier, J. P. PY - 2008 DA - 2008// TI - Rebuilding the R&D engine in big pharma JO - Harv Bus Rev VL - 86 ID - Garnier2008 ER - TY - JOUR AU - Douglas, F. L. PY - 2010 DA - 2010// TI - The case for entrepreneurship in R&D in the pharmaceutical industry JO - Nat Rev Drug Discov VL - 9 UR - https://doi.org/10.1038/nrd3230 DO - 10.1038/nrd3230 ID - Douglas2010 ER - TY - JOUR AU - Tralau-Stewart, C. J. PY - 2009 DA - 2009// TI - Drug discovery: new models for industry-academic partnerships JO - Drug Discov Today VL - 14 UR - https://doi.org/10.1016/j.drudis.2008.10.003 DO - 10.1016/j.drudis.2008.10.003 ID - Tralau-Stewart2009 ER - TY - JOUR AU - Regalado, A. PY - 2012 DA - 2012// TI - Money seeks idea. MIT JO - Technol Rev VL - 115 ID - Regalado2012 ER - TY - JOUR AU - Ekins, S. PY - 2013 DA - 2013// TI - Four disruptive strategies for removing drug discovery bottlenecks JO - Drug Discov Today VL - 18 UR - https://doi.org/10.1016/j.drudis.2012.10.007 DO - 10.1016/j.drudis.2012.10.007 ID - Ekins2013 ER - TY - JOUR AU - Frye, S. PY - 2011 DA - 2011// TI - US academic drug discovery JO - Nat Rev Drug Discov VL - 10 UR - https://doi.org/10.1038/nrd3462 DO - 10.1038/nrd3462 ID - Frye2011 ER - TY - JOUR AU - Kling, J. PY - 2011 DA - 2011// TI - Biotechs follow big pharma lead back into academia JO - Nat Biotechnol VL - 29 UR - https://doi.org/10.1038/nbt0711-555 DO - 10.1038/nbt0711-555 ID - Kling2011 ER - TY - JOUR AU - Schuhmacher, A. PY - 2013 DA - 2013// TI - Models for open innovation in the pharmaceutical industry JO - Drug Discov Today VL - 18 UR - https://doi.org/10.1016/j.drudis.2013.07.013 DO - 10.1016/j.drudis.2013.07.013 ID - Schuhmacher2013 ER - TY - STD TI - Citeline. Pharma R&D annual review. 2013. http://www.citeline.com/wp-content/uploads/Annual-Review-2014b.pdf. Accessed 28 Oct 2014. UR - http://www.citeline.com/wp-content/uploads/Annual-Review-2014b.pdf ID - ref45 ER - TY - STD TI - KPMG. Outsourcing in the pharmaceutical industry: 2011 and beyond. 2012 https://www.kpmg.com/Ca/en/IssuesAndInsights/ArticlesPublications/Documents/Outsourcing-pharmaceutical-industry.pdf. Accessed 15 Mar 2016. UR - https://www.kpmg.com/Ca/en/IssuesAndInsights/ArticlesPublications/Documents/Outsourcing-pharmaceutical-industry.pdf ID - ref46 ER - TY - JOUR AU - Mehta, S. AU - Peters, L. S. PY - 2007 DA - 2007// TI - Outsourcing a core competency JO - Res Technol Manag VL - 5 ID - Mehta2007 ER - TY - JOUR AU - Clark, D. E. PY - 2010 DA - 2010// TI - Outsourcing lead optimization: the eye of the storm JO - Drug Discov Today VL - 16 UR - https://doi.org/10.1016/j.drudis.2010.11.012 DO - 10.1016/j.drudis.2010.11.012 ID - Clark2010 ER - TY - JOUR AU - Kermani, F. PY - 2014 DA - 2014// TI - Drug discovery partnerships between UK CROs and the Swiss pharma sector JO - Pharm Technol Eur VL - 26 ID - Kermani2014 ER - TY - JOUR AU - Levy, H. PY - 2013 DA - 2013// TI - Integrated outsourcing transforms and increases R&D productivity JO - J Commer Biotechnol VL - 19 UR - https://doi.org/10.5912/jcb635 DO - 10.5912/jcb635 ID - Levy2013 ER - TY - JOUR AU - Ratner, M. PY - 2011 DA - 2011// TI - Pfizer reaches out to academia—again JO - Nat Biotechnol VL - 29 UR - https://doi.org/10.1038/nbt0111-3 DO - 10.1038/nbt0111-3 ID - Ratner2011 ER - TY - JOUR AU - Harrison, C. PY - 2011 DA - 2011// TI - GlaxoSmithKline opens the door on clinical data sharing JO - Nat Rev Drug Discov VL - 11 UR - https://doi.org/10.1038/nrd3907 DO - 10.1038/nrd3907 ID - Harrison2011 ER - TY - JOUR AU - Strauss, S. PY - 2010 DA - 2010// TI - Pharma embraces open source models JO - Nat Biotechnol VL - 7 UR - https://doi.org/10.1038/nbt0710-631 DO - 10.1038/nbt0710-631 ID - Strauss2010 ER - TY - JOUR AU - Munos, B. PY - 2010 DA - 2010// TI - Can open-source drug R&D repower pharmaceutical innovation? JO - Clin Pharmacol Ther VL - 87 UR - https://doi.org/10.1038/clpt.2010.26 DO - 10.1038/clpt.2010.26 ID - Munos2010 ER - TY - JOUR AU - Roijakkers, N. AU - Hagedorn, J. PY - 2006 DA - 2006// TI - Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: trends, patterns, and networks JO - Res Policy VL - 35 UR - https://doi.org/10.1016/j.respol.2006.01.006 DO - 10.1016/j.respol.2006.01.006 ID - Roijakkers2006 ER - TY - JOUR AU - Lessl, M. PY - 2011 DA - 2011// TI - Grants4Targets– an innovative approach to translate ideas from basic research into novel drugs JO - Drug Discov Today VL - 16 UR - https://doi.org/10.1016/j.drudis.2010.11.013 DO - 10.1016/j.drudis.2010.11.013 ID - Lessl2011 ER - TY - JOUR AU - Dorsch, H. PY - 2015 DA - 2015// TI - Grants4Targets—an open innovation initiative to foster drug discovery collaborations between academia and the pharmaceutical industry JO - Nat Rev Drug Discov VL - 14 UR - https://doi.org/10.1038/nrd3078-c2 DO - 10.1038/nrd3078-c2 ID - Dorsch2015 ER - TY - JOUR AU - Owens, P. K. PY - 2015 DA - 2015// TI - A decade of innovation in pharmaceutical R&D: the Chorus model JO - Nat Rev Drug Discov VL - 14 UR - https://doi.org/10.1038/nrd4497 DO - 10.1038/nrd4497 ID - Owens2015 ER - TY - JOUR AU - Longman, R. PY - 2007 DA - 2007// TI - Lilly‘s chorus experiment JO - In Vivo VL - 25 ID - Longman2007 ER - TY - STD TI - PWC. Pharma emerging markets 2.0. 2013. http://www.strategyand.pwc.com/media/file/Strategyand_Pharma-Emerging-Markets-2.0.pdf. Accessed 15 Nov 2015. UR - http://www.strategyand.pwc.com/media/file/Strategyand_Pharma-Emerging-Markets-2.0.pdf ID - ref60 ER - TY - STD TI - KPMG. Future Pharma. 2011. https://www.kpmg.com/BE/en/IssuesAndInsights/ArticlesPublications/Documents/future-pharma.pdf. Accessed 15 Nov 2015. UR - https://www.kpmg.com/BE/en/IssuesAndInsights/ArticlesPublications/Documents/future-pharma.pdf ID - ref61 ER -